Equities research analysts expect Omnicell, Inc. (NASDAQ:OMCL) to announce $177.37 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Omnicell’s earnings, with estimates ranging from $177.32 million to $177.41 million. Omnicell reported sales of $150.55 million during the same quarter last year, which would suggest a positive year over year growth rate of 17.8%. The company is expected to issue its next earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that Omnicell will report full-year sales of $177.37 million for the current financial year, with estimates ranging from $788.21 million to $790.51 million. For the next year, analysts expect that the company will post sales of $879.58 million per share, with estimates ranging from $867.46 million to $898.15 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Omnicell.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.02. The firm had revenue of $198.26 million for the quarter, compared to analyst estimates of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. Omnicell’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.37 earnings per share.

Several equities research analysts recently weighed in on OMCL shares. Cantor Fitzgerald increased their price objective on shares of Omnicell to $58.00 and gave the stock an “overweight” rating in a research note on Friday, October 27th. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. BidaskClub lowered shares of Omnicell from a “sell” rating to a “strong sell” rating in a research note on Friday, January 19th. Oppenheimer reiterated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Thursday, October 19th. Finally, Craig Hallum restated a “buy” rating and issued a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $56.14.

Shares of Omnicell (NASDAQ:OMCL) opened at $41.00 on Friday. The firm has a market cap of $1,555.21, a PE ratio of 80.39, a P/E/G ratio of 3.38 and a beta of 0.65. Omnicell has a 12 month low of $35.00 and a 12 month high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73.

In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares in the company, valued at approximately $2,095,719.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Peter J. Kuipers sold 4,724 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the completion of the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at approximately $1,935,570.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,263 shares of company stock valued at $1,023,726. 3.77% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. Janus Henderson Group PLC grew its position in Omnicell by 129.6% in the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after purchasing an additional 695,334 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Omnicell by 36.8% in the fourth quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after acquiring an additional 367,687 shares in the last quarter. Braun Stacey Associates Inc. bought a new position in shares of Omnicell in the fourth quarter valued at approximately $9,391,000. BlackRock Inc. boosted its holdings in shares of Omnicell by 4.0% in the fourth quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock valued at $234,701,000 after acquiring an additional 187,069 shares in the last quarter. Finally, Conestoga Capital Advisors LLC boosted its holdings in shares of Omnicell by 10.8% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,792,313 shares of the company’s stock valued at $86,927,000 after acquiring an additional 174,607 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $177.37 Million” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/11/zacks-brokerages-expect-omnicell-inc-omcl-will-announce-quarterly-sales-of-177-37-million.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.